Cargando…

Obesity risk is associated with altered cerebral glucose metabolism and decreased μ-opioid and CB(1) receptor availability

BACKGROUND: Obesity is a pressing public health concern worldwide. Novel pharmacological means are urgently needed to combat the increase of obesity and accompanying type 2 diabetes (T2D). Although fully established obesity is associated with neuromolecular alterations and insulin resistance in the...

Descripción completa

Detalles Bibliográficos
Autores principales: Kantonen, Tatu, Pekkarinen, Laura, Karjalainen, Tomi, Bucci, Marco, Kalliokoski, Kari, Haaparanta-Solin, Merja, Aarnio, Richard, Dickens, Alex M., von Eyken, Annie, Laitinen, Kirsi, Houttu, Noora, Kirjavainen, Anna K., Helin, Semi, Hirvonen, Jussi, Rönnemaa, Tapani, Nuutila, Pirjo, Nummenmaa, Lauri
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8794779/
https://www.ncbi.nlm.nih.gov/pubmed/34728775
http://dx.doi.org/10.1038/s41366-021-00996-y
_version_ 1784640896747175936
author Kantonen, Tatu
Pekkarinen, Laura
Karjalainen, Tomi
Bucci, Marco
Kalliokoski, Kari
Haaparanta-Solin, Merja
Aarnio, Richard
Dickens, Alex M.
von Eyken, Annie
Laitinen, Kirsi
Houttu, Noora
Kirjavainen, Anna K.
Helin, Semi
Hirvonen, Jussi
Rönnemaa, Tapani
Nuutila, Pirjo
Nummenmaa, Lauri
author_facet Kantonen, Tatu
Pekkarinen, Laura
Karjalainen, Tomi
Bucci, Marco
Kalliokoski, Kari
Haaparanta-Solin, Merja
Aarnio, Richard
Dickens, Alex M.
von Eyken, Annie
Laitinen, Kirsi
Houttu, Noora
Kirjavainen, Anna K.
Helin, Semi
Hirvonen, Jussi
Rönnemaa, Tapani
Nuutila, Pirjo
Nummenmaa, Lauri
author_sort Kantonen, Tatu
collection PubMed
description BACKGROUND: Obesity is a pressing public health concern worldwide. Novel pharmacological means are urgently needed to combat the increase of obesity and accompanying type 2 diabetes (T2D). Although fully established obesity is associated with neuromolecular alterations and insulin resistance in the brain, potential obesity-promoting mechanisms in the central nervous system have remained elusive. In this triple-tracer positron emission tomography study, we investigated whether brain insulin signaling, μ-opioid receptors (MORs) and cannabinoid CB(1) receptors (CB(1)Rs) are associated with risk for developing obesity. METHODS: Subjects were 41 young non-obese males with variable obesity risk profiles. Obesity risk was assessed by subjects’ physical exercise habits, body mass index and familial risk factors, including parental obesity and T2D. Brain glucose uptake was quantified with [(18)F]FDG during hyperinsulinemic euglycemic clamp, MORs were quantified with [(11)C]carfentanil and CB(1)Rs with [(18)F]FMPEP-d(2). RESULTS: Subjects with higher obesity risk had globally increased insulin-stimulated brain glucose uptake (19 high-risk subjects versus 19 low-risk subjects), and familial obesity risk factors were associated with increased brain glucose uptake (38 subjects) but decreased availability of MORs (41 subjects) and CB(1)Rs (36 subjects). CONCLUSIONS: These results suggest that the hereditary mechanisms promoting obesity may be partly mediated via insulin, opioid and endocannabinoid messaging systems in the brain.
format Online
Article
Text
id pubmed-8794779
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-87947792022-02-07 Obesity risk is associated with altered cerebral glucose metabolism and decreased μ-opioid and CB(1) receptor availability Kantonen, Tatu Pekkarinen, Laura Karjalainen, Tomi Bucci, Marco Kalliokoski, Kari Haaparanta-Solin, Merja Aarnio, Richard Dickens, Alex M. von Eyken, Annie Laitinen, Kirsi Houttu, Noora Kirjavainen, Anna K. Helin, Semi Hirvonen, Jussi Rönnemaa, Tapani Nuutila, Pirjo Nummenmaa, Lauri Int J Obes (Lond) Article BACKGROUND: Obesity is a pressing public health concern worldwide. Novel pharmacological means are urgently needed to combat the increase of obesity and accompanying type 2 diabetes (T2D). Although fully established obesity is associated with neuromolecular alterations and insulin resistance in the brain, potential obesity-promoting mechanisms in the central nervous system have remained elusive. In this triple-tracer positron emission tomography study, we investigated whether brain insulin signaling, μ-opioid receptors (MORs) and cannabinoid CB(1) receptors (CB(1)Rs) are associated with risk for developing obesity. METHODS: Subjects were 41 young non-obese males with variable obesity risk profiles. Obesity risk was assessed by subjects’ physical exercise habits, body mass index and familial risk factors, including parental obesity and T2D. Brain glucose uptake was quantified with [(18)F]FDG during hyperinsulinemic euglycemic clamp, MORs were quantified with [(11)C]carfentanil and CB(1)Rs with [(18)F]FMPEP-d(2). RESULTS: Subjects with higher obesity risk had globally increased insulin-stimulated brain glucose uptake (19 high-risk subjects versus 19 low-risk subjects), and familial obesity risk factors were associated with increased brain glucose uptake (38 subjects) but decreased availability of MORs (41 subjects) and CB(1)Rs (36 subjects). CONCLUSIONS: These results suggest that the hereditary mechanisms promoting obesity may be partly mediated via insulin, opioid and endocannabinoid messaging systems in the brain. Nature Publishing Group UK 2021-11-02 2022 /pmc/articles/PMC8794779/ /pubmed/34728775 http://dx.doi.org/10.1038/s41366-021-00996-y Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Kantonen, Tatu
Pekkarinen, Laura
Karjalainen, Tomi
Bucci, Marco
Kalliokoski, Kari
Haaparanta-Solin, Merja
Aarnio, Richard
Dickens, Alex M.
von Eyken, Annie
Laitinen, Kirsi
Houttu, Noora
Kirjavainen, Anna K.
Helin, Semi
Hirvonen, Jussi
Rönnemaa, Tapani
Nuutila, Pirjo
Nummenmaa, Lauri
Obesity risk is associated with altered cerebral glucose metabolism and decreased μ-opioid and CB(1) receptor availability
title Obesity risk is associated with altered cerebral glucose metabolism and decreased μ-opioid and CB(1) receptor availability
title_full Obesity risk is associated with altered cerebral glucose metabolism and decreased μ-opioid and CB(1) receptor availability
title_fullStr Obesity risk is associated with altered cerebral glucose metabolism and decreased μ-opioid and CB(1) receptor availability
title_full_unstemmed Obesity risk is associated with altered cerebral glucose metabolism and decreased μ-opioid and CB(1) receptor availability
title_short Obesity risk is associated with altered cerebral glucose metabolism and decreased μ-opioid and CB(1) receptor availability
title_sort obesity risk is associated with altered cerebral glucose metabolism and decreased μ-opioid and cb(1) receptor availability
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8794779/
https://www.ncbi.nlm.nih.gov/pubmed/34728775
http://dx.doi.org/10.1038/s41366-021-00996-y
work_keys_str_mv AT kantonentatu obesityriskisassociatedwithalteredcerebralglucosemetabolismanddecreasedmopioidandcb1receptoravailability
AT pekkarinenlaura obesityriskisassociatedwithalteredcerebralglucosemetabolismanddecreasedmopioidandcb1receptoravailability
AT karjalainentomi obesityriskisassociatedwithalteredcerebralglucosemetabolismanddecreasedmopioidandcb1receptoravailability
AT buccimarco obesityriskisassociatedwithalteredcerebralglucosemetabolismanddecreasedmopioidandcb1receptoravailability
AT kalliokoskikari obesityriskisassociatedwithalteredcerebralglucosemetabolismanddecreasedmopioidandcb1receptoravailability
AT haaparantasolinmerja obesityriskisassociatedwithalteredcerebralglucosemetabolismanddecreasedmopioidandcb1receptoravailability
AT aarniorichard obesityriskisassociatedwithalteredcerebralglucosemetabolismanddecreasedmopioidandcb1receptoravailability
AT dickensalexm obesityriskisassociatedwithalteredcerebralglucosemetabolismanddecreasedmopioidandcb1receptoravailability
AT voneykenannie obesityriskisassociatedwithalteredcerebralglucosemetabolismanddecreasedmopioidandcb1receptoravailability
AT laitinenkirsi obesityriskisassociatedwithalteredcerebralglucosemetabolismanddecreasedmopioidandcb1receptoravailability
AT houttunoora obesityriskisassociatedwithalteredcerebralglucosemetabolismanddecreasedmopioidandcb1receptoravailability
AT kirjavainenannak obesityriskisassociatedwithalteredcerebralglucosemetabolismanddecreasedmopioidandcb1receptoravailability
AT helinsemi obesityriskisassociatedwithalteredcerebralglucosemetabolismanddecreasedmopioidandcb1receptoravailability
AT hirvonenjussi obesityriskisassociatedwithalteredcerebralglucosemetabolismanddecreasedmopioidandcb1receptoravailability
AT ronnemaatapani obesityriskisassociatedwithalteredcerebralglucosemetabolismanddecreasedmopioidandcb1receptoravailability
AT nuutilapirjo obesityriskisassociatedwithalteredcerebralglucosemetabolismanddecreasedmopioidandcb1receptoravailability
AT nummenmaalauri obesityriskisassociatedwithalteredcerebralglucosemetabolismanddecreasedmopioidandcb1receptoravailability